6 active not recruiting. 6 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Active not recruiting 6 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Liposarcoma: new trials by email Literature Review of Liposarcoma trials Research Report on Liposarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma BTX-A51 - Liposarcoma, Recurrent Liposarcoma | Phase 1 | Active not recruiting | Michael Wagner, MD | 24 | 2024-09-30 | 2026-07-01 |
| BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors CAR-GPC3 T Cells - Hepatocellular Carcinoma, Squamous Cell Carcinoma of the Lung | Phase 1 / Phase 2 | Active not recruiting | Sotio Biotech Inc. | 7 | 2022-10-26 | 2025-12-05 |
| Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors AGAR T cells - Liver Cancer, Rhabdomyosarcoma | Phase 1 | Active not recruiting | Baylor College of Medicine | 14 | 2021-08-08 | 2026-01-21 |
| Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors CATCH T cells - Liver Cell Carcinoma, Solid Tumor | Phase 1 | Active not recruiting | Baylor College of Medicine | 12 | 2021-06-17 | 2026-03-06 |
| Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery Eribulin Mesylate, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis - Liposarcoma, Malignant Abdominal Neoplasm | Phase 1 | Active not recruiting | OHSU Knight Cancer Institute | 15 | 2018-03-19 | 2026-04-08 |
| MAGE-A4ᶜ¹º³²T for Multi-Tumor Autologous genetically modified MAGE-A4ᶜ¹º³²T cells, Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation - Urinary Bladder Cancer, Melanoma | Phase 1 | Active not recruiting | USWM CT, LLC | 71 | 2017-05-15 | 2026-06-04 |
Liposarcoma, Myxoid (3) · Carcinoma, Hepatocellular (2) · Endodermal Sinus Tumor (2) · Liver Neoplasms (2) · Rhabdoid Tumor (2) · Rhabdomyosarcoma (2) · Wilms Tumor (2) · Adenocarcinoma (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Esophageal Neoplasms (1) · Head and Neck Neoplasms (1) · Melanoma (1) · Neoplasm Metastasis (1)
Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms, Adipose Tissue (6) · Neoplasms, Connective and Soft Tissue (6) · Sarcoma (5) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Neoplasms by Site (4) · Neoplasms, Germ Cell and Embryonal (4) · Carcinoma (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Liver Diseases (3) · Male Urogenital Diseases (3) · Neoplasms, Glandular and Epithelial (3)
Radiation (1) · Radiotherapy, Intensity-Modulated (1) · eribulin (1)
Baylor College of Medicine (2) · Michael Wagner, MD (1) · OHSU Knight Cancer Institute (1) · Sotio Biotech Inc. (1) · USWM CT, LLC (1)
United States (6) · Canada (1) · United Kingdom (1)
David Hong, MD (1) · David Steffin, MD (1) · Lara E Davis (1) · Michael Wagner, MD (1) · Pauline Duhard, Pharm.D. (1) · Tannaz Armaghany, MD (1)
PMID 32002290, PMID 32827353, PMID 35507536, PMID 36624315, PMID 42501677